An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice (MIROIR)

Celgene

Status: Completed

Conditions: Multiple Myeloma

Study type: Observational

Funder types: Industry

Identifiers

NCT02902900

CC-4047-MM-018

Details and patient eligibility

About

This study, a national, multicenter, observational, ambispective, non-interventional study, will be conducted in French hospitals prescribing pomalidomide and already participating in the ongoing Imnovid registry.

This study will add to the registry. Indeed, pomalidomide-prescribing physicians and pharmacists dispensing pomalidomide have to enter into the Imnovid registry all patients who have been prescribed this drug since the date on which it was marketed regardless of the initiation date of pomalidomide or the indication for which it was prescribed.

Enrollment: 2,504 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient (age ≥ 18 yrs),
• Diagnosed with multiple myeloma (measurable or not),
• In whom pomalidomide treatment was first initiated between October 1, 2014, and September 30, 2019,
• Patient already included in the Imnovid registry,
• Having received oral and written information about the study, and having given their consent to participate.

Exclusion criteria

• Previous participation in a clinical trial with pomalidomide,
• Treatment with pomalidomide in a previous line,
• Simultaneous participation in a clinical trial.

Trial design

2,504 participants in 1 patient group

Imnovid

Description:

Patients relapse/ refractory multiple myeloma who initiated pomalidomide in routine clinical practice